Abiopharma

Steinhart Richard I 🟢 acquired 70.0K shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) Transaction Date: Jan 01, 2026 | Filing ID: 000837

Director Mehta Vimal 🟢 acquired 199.0K shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) Transaction Date: Jan 01, 2026 | Filing ID: 000835

Rodriguez Javier 🟢 acquired 70.0K shares (1 derivative) of BioXcel Therapeutics, Inc. (BTAI) Transaction Date: Jan 01, 2026 | Filing ID: 000834

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China

San Martin Javier 🟡 adjusted position in 1.6K shares (1 derivative) of Athira Pharma, Inc. (ATHA) at $6.88 Transaction Date: Dec 31, 2025 | Filing ID: 000002

Litton Mark James 🟡 adjusted position in 2.6K shares (1 derivative) of Athira Pharma, Inc. (ATHA) at $6.88 Transaction Date: Dec 31, 2025 | Filing ID: 000002

Renninger Robert 🟡 adjusted position in 703 shares (1 derivative) of Athira Pharma, Inc. (ATHA) at $6.88 Transaction Date: Dec 31, 2025 | Filing ID: 000002

CHURCH KEVIN 🟡 adjusted position in 124 shares (1 derivative) of Athira Pharma, Inc. (ATHA) at $6.88 Transaction Date: Dec 31, 2025 | Filing ID: 000002

📋 Jula Inrig (Officer) plans to sell 2K shares of Travere Therapeutics, Inc. (at $40.18 each, total $82K) Filed: Jan 05, 2026 | ID: 003062

Worthington Mark 🟡 adjusted position in 876 shares (1 derivative) of Athira Pharma, Inc. (ATHA) at $6.88 Transaction Date: Dec 31, 2025 | Filing ID: 000002

Director Manieu Alexandre Weinstein 🟢 acquired 1.2M shares (1 derivative) of Pluri Inc. (PLUR) at $4.25 ($3.9M) Transaction Date: Dec 30, 2025 | Filing ID: 001394

New Form SCHEDULE 13D/A - Pluri Inc. Filed: 2026-01-05 AccNo: 0001213900-26-001393 Size: 32 KB

New Form 3 - HALOZYME THERAPEUTICS, INC. Filed: 2026-01-05 AccNo: 0001159036-26-000004 Size: 639 KB

Director MARTELL RON 🟢 acquired 234.0K shares (1 derivative) of Jasper Therapeutics, Inc. (JSPR) at $1.84 Transaction Date: Jan 02, 2026 | Filing ID: 001385

Mahal Jeetinder Singh 🟢 acquired 90.0K shares (1 derivative) of Jasper Therapeutics, Inc. (JSPR) at $1.84 Transaction Date: Jan 02, 2026 | Filing ID: 001383